Phase articles organized by Serendeputy, newsfeed engine for the open web

Phase tag sponsored by:

The Phase: Shattering the Illusion of Reality

Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies – NovoCur
breakingnow.co | 3 hours ago | Article Details | Related Articles
Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020
wtvm.com | yesterday | Article Details | Related Articles
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
cohbar.com | yesterday | Article Details | Related Articles
Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting - SDN - Science & Digital News
scitechanddigital.news | 13 hours ago | Article Details | Related Articles
Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting – Padovanews
padovanews.it | 7 hours ago | Article Details | Related Articles
CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023 – Catalym
catalym.com | yesterday | Article Details | Related Articles
- Antibody
- Ascó
- Combination
- Nivolumab
- Phase
- 195 Tags
- 1 Feed
Datopotamab deruxtecan combinations showed encouraging tumour responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
tanalys.se | yesterday | Article Details | Related Articles
- Advanced
- Ib Trial
- Lung cancer
- Neoplasm
- Phase
- 223 Tags
- 1 Feed
4-12 months Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipi
todaysstocks.com | yesterday | Article Details | Related Articles
- Durable
- Ipilimumab
- Nivolumab
- Phase 3
- Survival
- 290 Tags
- 1 Feed
Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023
floridalatamworldofbusiness.com | yesterday | Article Details | Related Articles
Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting : Cronaca di Sicilia
cronacadisicilia.it | yesterday | Article Details | Related Articles
Innovent Updates Phase 1b Data Of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined With Sintilimab In Previously Untreated PD-L1-selected NSCLC At The 2023 ASCO Annual Meeting - Medical Device News Magazine
infomeddnews.com | yesterday | Article Details | Related Articles
Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting
localpage.eu | yesterday | Article Details | Related Articles
Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting - SDN - Science & Digital News
scitechanddigital.news | yesterday | Article Details | Related Articles
- Ascó
- Clinical
- Monoclonal antibody
- Presents
- Science
- 289 Tags
- 1 Feed
Oncolytics Biotech® Publicizes Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareo
todaysstocks.com | 23 hours ago | Article Details | Related Articles
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference - Psychedelic Alpha
psychedelicalpha.com | 4 hours ago | Article Details | Related Articles
- Cough
- Ifenprodil
- Pharmaceutical drug
- PHASE 2
- Psychedelic
- 178 Tags
- 1 Feed
Tagrisso achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five yearsin ADAURA Phase III trial
tanalys.se | yesterday | Article Details | Related Articles
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
resourcenews.com | 4 hours ago | Article Details | Related Articles
- 2023
- Data
- Ifenprodil
- Pharmaceutical drug
- PHASE 2
- 184 Tags
- 1 Feed
Puma Biotechnology Broadcasts Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Pacli
todaysstocks.com | yesterday | Article Details | Related Articles
- Alisertib
- Biomarker
- Paclitaxel
- Phase II
- Puma Biotechnology
- 220 Tags
- 1 Feed
ASCO: BMS’ Opdivo challenges Seagen’s Adcetris with Phase III win – PharmaLive
pharmalive.com | yesterday | Article Details | Related Articles
- Ascó
- Brentuximab vedotin
- Nivolumab
- Phase III
- SeaGen
- 132 Tags
- 1 Feed
Rabies vaccine gets phase 3 trial approval
labiotech.eu | yesterday | Article Details | Related Articles
- Approval
- Immunogenicity
- Phase 3
- Rabies vaccine
- Trial
- 153 Tags
- 1 Feed
NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting | NKGen Biotech
nkgenbiotech.com | 7 hours ago | Article Details | Related Articles
Synlogic begins Phase III trial of SYNB1934 for phenylketonuria
clinicaltrialsarena.com | 1 hour ago | Article Details | Related Articles
Cocrystal receives approval from HREC for Phase I trial - DirectorsTalk
directorstalk.net | 2 hours ago | Article Details | Related Articles
Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial | IT Business Net
itbusinessnet.com | yesterday | Article Details | Related Articles
- 1B
- Clinical trial
- Glioblastoma
- Launch
- Phase
- 200 Tags
- 1 Feed
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
1vynd53k72.execute-api.us-east-1.amazonaws.com | yesterday | Article Details | Related Articles
- Antibody
- Disease
- Multiple sclerosis
- PHASE 2
- Relapse
- 270 Tags
- 1 Post
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
jitc.bmj.com | yesterday | Article Details | Related Articles
- Angiosarcoma
- CTLA-4
- Ipilimumab
- Nivolumab
- SWOG
- 282 Tags
- 1 Post
Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GHRA), AZP-3813, for Acromegaly | Amolyt Pharma
amolytpharma.com | yesterday | Article Details | Related Articles
Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies - Psychedelic Alpha
psychedelicalpha.com | yesterday | Article Details | Related Articles
Erasca To Present Promising Preliminary Herkules-3 Phase 1B Data At The 2023 ASCO Annual Meeting - Tarsadia
tarsadia.com | yesterday | Article Details | Related Articles
- 1B
- Annual general meeting
- Ascó
- Phase
- Preliminary
- 280 Tags
- 1 Feed
Phase 3 Mesothelioma Study Shows Significant Improvement from Keytruda Plus Chemotherapy - Mesothelioma.net
mesothelioma.net | 23 hours ago | Article Details | Related Articles
Clinical Trial: Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (incl Neuroendocrine Neoplasms)
ronnyallan.net | yesterday | Article Details | Related Articles
Medaro Mining Commenced Phase 2 Exploration Work on the Darlin Lithium Property in Quebec
resourcenews.com | 5 hours ago | Article Details | Related Articles
- Exploration
- Lithium
- Mining
- Property
- Quebec
- 159 Tags
- 1 Feed
Defender Pharmaceuticals Reports Positive Results from Pivotal Phase III Clinical Trial of Intranasal Scopolamine for the Prevention of Nausea and Vomiting Induced by Motion | IT Business Net
itbusinessnet.com | 23 hours ago | Article Details | Related Articles
Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care
tanalys.se | yesterday | Article Details | Related Articles
Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting - Elicio
elicio.com | 16 hours ago | Article Details | Related Articles
AstraZeneca reports positive results from ADAURA Phase III trial
clinicaltrialsarena.com | yesterday | Article Details | Related Articles
Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting – SHQ
sustainabilityhq.com | 14 hours ago | Article Details | Related Articles
Phase 1 of Dubai Investments’ Danah Bay in Ras Al Khaimah fully sold out
emirates247.com | yesterday | Article Details | Related Articles
- Danah Bay
- Dubai
- Investment
- Phase 1
- Sold Out
- 102 Tags
- 1 Feed
Dr. Reddy’s successfully completes Phase I study of its proposed biosimilar of immunosuppressive drug - G6
gsix.org | yesterday | Article Details | Related Articles
Airway Therapeutics Completes Enrollment in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia – Global Press Release Centre
newspressreleasesite.com | yesterday | Article Details | Related Articles
Prolong Pharmaceuticals Announces Presentation of Phase 1 Data from HEMERA-1 Clinical Study of PP-007 in Patients with Acute Ischemic Stroke at the Late-Breaking Science Session, ISC 2023 - Tarsadia
tarsadia.com | 23 hours ago | Article Details | Related Articles
- Clinical trial
- Ischemia
- Pharmaceutical drug
- Science
- Stroke
- 157 Tags
- 1 Feed
Akero’s NASH candidate and Ozempic reduce liver fat in Phase IIb cohort
clinicaltrialsarena.com | yesterday | Article Details | Related Articles
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting – Bio Tech Winners
biotechwinners.com | 20 hours ago | Article Details | Related Articles
Six months to deadline: is your ESOS reporting ready for the strengthened Phase 3? – Energy Advice Hub
energyadvicehub.org | yesterday | Article Details | Related Articles
- Advice
- Deadline
- Enterprise Storage OS
- Phase 3
- Reporting
- 140 Tags
- 1 Feed
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial | IT Business Net
itbusinessnet.com | 2 days ago | Article Details | Related Articles
Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting | IT Business N
itbusinessnet.com | 3 days ago | Article Details | Related Articles
NovelMed Phase I Clinical Trial Shows Inhibition of the
europeanartnews.com | yesterday | Article Details | Related Articles
Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy
samacharlive.com | yesterday | Article Details | Related Articles

The custom newsfeed you control

Phase

The Phase: Shattering the Illusion of Reality

Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies – NovoCur

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting - SDN - Science & Digital News

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting – Padovanews

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023 – Catalym

Datopotamab deruxtecan combinations showed encouraging tumour responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial

4-12 months Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipi

Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting : Cronaca di Sicilia

Innovent Updates Phase 1b Data Of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined With Sintilimab In Previously Untreated PD-L1-selected NSCLC At The 2023 ASCO Annual Meeting - Medical Device News Magazine

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting

Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting - SDN - Science & Digital News

Oncolytics Biotech® Publicizes Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareo

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference - Psychedelic Alpha

Tagrisso achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five yearsin ADAURA Phase III trial

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

Puma Biotechnology Broadcasts Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Pacli

ASCO: BMS’ Opdivo challenges Seagen’s Adcetris with Phase III win – PharmaLive

Rabies vaccine gets phase 3 trial approval

NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting | NKGen Biotech

Synlogic begins Phase III trial of SYNB1934 for phenylketonuria

Cocrystal receives approval from HREC for Phase I trial - DirectorsTalk

Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial | IT Business Net

Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GHRA), AZP-3813, for Acromegaly | Amolyt Pharma

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies - Psychedelic Alpha

Erasca To Present Promising Preliminary Herkules-3 Phase 1B Data At The 2023 ASCO Annual Meeting - Tarsadia

Phase 3 Mesothelioma Study Shows Significant Improvement from Keytruda Plus Chemotherapy - Mesothelioma.net

Clinical Trial: Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (incl Neuroendocrine Neoplasms)

Medaro Mining Commenced Phase 2 Exploration Work on the Darlin Lithium Property in Quebec

Defender Pharmaceuticals Reports Positive Results from Pivotal Phase III Clinical Trial of Intranasal Scopolamine for the Prevention of Nausea and Vomiting Induced by Motion | IT Business Net

Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting - Elicio

AstraZeneca reports positive results from ADAURA Phase III trial

Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting – SHQ

Phase 1 of Dubai Investments’ Danah Bay in Ras Al Khaimah fully sold out

Dr. Reddy’s successfully completes Phase I study of its proposed biosimilar of immunosuppressive drug - G6

Airway Therapeutics Completes Enrollment in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia – Global Press Release Centre

Prolong Pharmaceuticals Announces Presentation of Phase 1 Data from HEMERA-1 Clinical Study of PP-007 in Patients with Acute Ischemic Stroke at the Late-Breaking Science Session, ISC 2023 - Tarsadia

Akero’s NASH candidate and Ozempic reduce liver fat in Phase IIb cohort

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting – Bio Tech Winners

Six months to deadline: is your ESOS reporting ready for the strengthened Phase 3? – Energy Advice Hub

Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial | IT Business Net

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting | IT Business N

NovelMed Phase I Clinical Trial Shows Inhibition of the

Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy